Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2020-05-19 Director's Dealing
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-05-19 English
FORM 4 SUBMISSION
Director's Dealing
2020-05-16 English
FORM 4 SUBMISSION
Director's Dealing
2020-05-16 English
10-Q
Interim / Quarterly Report Q1 2020
2020-05-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 12, 2020, by Vir Biotechnology, Inc. It specifically states in Item 2.02 that the company issued a press release announcing its financial results for the quarter ended March 31, 2020. The document includes the press release as Exhibit 99.1. The text clarifies that the information is being furnished and is not considered "filed" for certain legal purposes, which is typical for earnings releases. The document length is 3598 characters, which is relatively short and consistent with an earnings release announcement rather than a full quarterly report. The content focuses on announcing quarterly financial results, which aligns with the definition of an Earnings Release (ER). Therefore, the correct classification is Earnings Release (ER).
2020-05-12 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, specifically a Definitive Additional Materials supplement to a Proxy Statement for an Annual Meeting of Stockholders. It provides updated information about the change of the meeting format to virtual due to COVID-19, instructions for attending and voting, and other logistical details. It does not contain the proxy statement itself, nor detailed financial or governance reports, but rather supplements the proxy materials. This type of document is classified as Proxy Solicitation & Information Statement (PSI). The document length (7784 characters) and content confirm it is not a brief announcement or a full annual report but a proxy-related filing.
2020-05-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.